Pharmacokinetic analysis of hypoxia 18F-fluoromisonidazole dynamic PET in head and neck cancer

Journal of Nuclear Medicine

Volumn 51, Issue 1, 2010, Pages 37-45

  Wang, Wenli ^a   Lee, Nancy Y ^a   Georgi, Jens Christoph ^b   Narayanan, Manoj ^c   Guillem, Jose ^a   Scḧoder, Heiko ^a   Humm, John L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b PHILIPS RESEARCH LABORATORIES   (Germany)

^c PHILIPS RESEARCH LABORATORIES   (Netherlands)

Author keywords

18F FMISO; Head and neck cancer; Hypoxia; PET; Pharmacokinetics

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18;

ADULT; AGED; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG TRANSPORT; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL;

AGED; ANOXIA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MISONIDAZOLE; NEOPLASM STAGING; PLASMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW;

EID: 75149115119     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.067009     Document Type: Article

References (24)

1. Ḧockel M, Knoop C, Schlenger K, et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol. 1993;26:45-50.
2. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human whole-body sarcoma. Cancer Res. 1996;56:941-943.
3. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology. 2002;60:634-639.
4. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head-and-neck. Radiother Oncol. 1996;41:31-39.
5. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head-and-neck. Int J Radiat Oncol Biol Phys. 1997;38:285-289.
6. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 1999;44:749-754.
7. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head-and-neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77:18-24.
8. Valk PE, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluroromisonidazole. J Nucl Med. 1992;33:2133-2137.
9. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
10. 18F-misonidazole and PET: changes of kinetics during radiotherapy of head-andneck cancer. Radiother Oncol. 2007;83:406-410.
11. 18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia [abstract]? BMC Cancer. 2007;7:113.
12. Chapman JD, Lee J, Meeker BE. Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells. Int J Radiat Oncol Biol Phys. 1989;16:911-917.
13. Casciari J, Graham MM, Rasey JS. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med Phys. 1995;22:1127-1139.
14. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252.
15. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.
16. 18F]-Fmiso PET data to analyze tumor hypoxia. Phys Med Biol. 2005;50:2209-2224.
17. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer [abstract]. BMC Cancer. 2005;5:152.
18. Wang W, Georgi J-C, Nehmeh SA, et al. Evaluation of compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol. 2009;54:3083-3099.
19. Huang SC, Phelps ME. Principles of tracer kinetic modeling in positron emission tomography and autoradiography. In: Phelps M, Mazziotta J, Schelbert H, eds. New York, New York: Raven Press; 1986:287-345.
20. Wahl RL, Zasadny K, Helvie, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
21. Gupta N, Gill H, Graeber G, et al. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998;114:1105-1111.
22. Hoekstra CJ, Hoekstra OS, Lammertsma AA. On the use of image-derived input functions in oncological fluorine-18 fluorodeoxyglucose positron emission tomography studies. Eur J Nucl Med. 1999;26:1489-1492.
23. Jensen-Urstad K, Jensen-Urstad M, Johansson J. Carotid artery diameter correlates with risk factors for cardiovascular disease in a population of 55-year-old subjects. Stroke. 1999;30:1572-1576.
24. Hong TS, Tomé WA, Chappell RJ, et al. The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005;61:779-788.